767 related articles for article (PubMed ID: 17177598)
41. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways.
Sordella R; Bell DW; Haber DA; Settleman J
Science; 2004 Aug; 305(5687):1163-7. PubMed ID: 15284455
[TBL] [Abstract][Full Text] [Related]
42. Epidermal growth factor receptors harboring kinase domain mutations associate with the heat shock protein 90 chaperone and are destabilized following exposure to geldanamycins.
Shimamura T; Lowell AM; Engelman JA; Shapiro GI
Cancer Res; 2005 Jul; 65(14):6401-8. PubMed ID: 16024644
[TBL] [Abstract][Full Text] [Related]
43. Combined treatment with erlotinib and a transforming growth factor-β type I receptor inhibitor effectively suppresses the enhanced motility of erlotinib-resistant non-small-cell lung cancer cells.
Serizawa M; Takahashi T; Yamamoto N; Koh Y
J Thorac Oncol; 2013 Mar; 8(3):259-69. PubMed ID: 23334091
[TBL] [Abstract][Full Text] [Related]
44. Inhibition of the T790M gatekeeper mutant of the epidermal growth factor receptor by EXEL-7647.
Gendreau SB; Ventura R; Keast P; Laird AD; Yakes FM; Zhang W; Bentzien F; Cancilla B; Lutman J; Chu F; Jackman L; Shi Y; Yu P; Wang J; Aftab DT; Jaeger CT; Meyer SM; De Costa A; Engell K; Chen J; Martini JF; Joly AH
Clin Cancer Res; 2007 Jun; 13(12):3713-23. PubMed ID: 17575237
[TBL] [Abstract][Full Text] [Related]
45. Mutations within the kinase domain and truncations of the epidermal growth factor receptor are rare events in bladder cancer: implications for therapy.
Blehm KN; Spiess PE; Bondaruk JE; Dujka ME; Villares GJ; Zhao YJ; Bogler O; Aldape KD; Grossman HB; Adam L; McConkey DJ; Czerniak BA; Dinney CP; Bar-Eli M
Clin Cancer Res; 2006 Aug; 12(15):4671-7. PubMed ID: 16899617
[TBL] [Abstract][Full Text] [Related]
46. Epidermal growth factor receptor (EGFR) structure-based bioactive pharmacophore models for identifying next-generation inhibitors against clinically relevant EGFR mutations.
Panicker PS; Melge AR; Biswas L; Keechilat P; Mohan CG
Chem Biol Drug Des; 2017 Oct; 90(4):629-636. PubMed ID: 28303669
[TBL] [Abstract][Full Text] [Related]
47. Novel
Servidei T; Meco D; Muto V; Bruselles A; Ciolfi A; Trivieri N; Lucchini M; Morosetti R; Mirabella M; Martini M; Caldarelli M; Lasorella A; Tartaglia M; Riccardi R
Cancer Res; 2017 Nov; 77(21):5860-5872. PubMed ID: 29092923
[TBL] [Abstract][Full Text] [Related]
48. Identification of molecular characteristics correlated with glioblastoma sensitivity to EGFR kinase inhibition through use of an intracranial xenograft test panel.
Sarkaria JN; Yang L; Grogan PT; Kitange GJ; Carlson BL; Schroeder MA; Galanis E; Giannini C; Wu W; Dinca EB; James CD
Mol Cancer Ther; 2007 Mar; 6(3):1167-74. PubMed ID: 17363510
[TBL] [Abstract][Full Text] [Related]
49. Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors.
Vivanco I; Robins HI; Rohle D; Campos C; Grommes C; Nghiemphu PL; Kubek S; Oldrini B; Chheda MG; Yannuzzi N; Tao H; Zhu S; Iwanami A; Kuga D; Dang J; Pedraza A; Brennan CW; Heguy A; Liau LM; Lieberman F; Yung WK; Gilbert MR; Reardon DA; Drappatz J; Wen PY; Lamborn KR; Chang SM; Prados MD; Fine HA; Horvath S; Wu N; Lassman AB; DeAngelis LM; Yong WH; Kuhn JG; Mischel PS; Mehta MP; Cloughesy TF; Mellinghoff IK
Cancer Discov; 2012 May; 2(5):458-71. PubMed ID: 22588883
[TBL] [Abstract][Full Text] [Related]
50. EGFR Mutation Promotes Glioblastoma through Epigenome and Transcription Factor Network Remodeling.
Liu F; Hon GC; Villa GR; Turner KM; Ikegami S; Yang H; Ye Z; Li B; Kuan S; Lee AY; Zanca C; Wei B; Lucey G; Jenkins D; Zhang W; Barr CL; Furnari FB; Cloughesy TF; Yong WH; Gahman TC; Shiau AK; Cavenee WK; Ren B; Mischel PS
Mol Cell; 2015 Oct; 60(2):307-18. PubMed ID: 26455392
[TBL] [Abstract][Full Text] [Related]
51. Epithelial growth factor receptor expression influences 5-ALA induced glioblastoma fluorescence.
Fontana AO; Piffaretti D; Marchi F; Burgio F; Faia-Torres AB; Paganetti P; Pinton S; Pieles U; Reinert M
J Neurooncol; 2017 Jul; 133(3):497-507. PubMed ID: 28500562
[TBL] [Abstract][Full Text] [Related]
52. Compounds identified by virtual docking to a tetrameric EGFR extracellular domain can modulate Grb2 internalization.
Ramirez UD; Nikonova AS; Liu H; Pecherskaya A; Lawrence SH; Serebriiskii IG; Zhou Y; Robinson MK; Einarson MB; Golemis EA; Jaffe EK
BMC Cancer; 2015 May; 15():436. PubMed ID: 26016476
[TBL] [Abstract][Full Text] [Related]
53. Epidermal growth factor receptor as a therapeutic target in glioblastoma.
Kalman B; Szep E; Garzuly F; Post DE
Neuromolecular Med; 2013 Jun; 15(2):420-34. PubMed ID: 23575987
[TBL] [Abstract][Full Text] [Related]
54. New anti-cancer chemicals Ertredin and its derivatives, regulate oxidative phosphorylation and glycolysis and suppress sphere formation in vitro and tumor growth in EGFRvIII-transformed cells.
Atsumi S; Nosaka C; Adachi H; Kimura T; Kobayashi Y; Takada H; Watanabe T; Ohba S; Inoue H; Kawada M; Shibasaki M; Shibuya M
BMC Cancer; 2016 Jul; 16():496. PubMed ID: 27431653
[TBL] [Abstract][Full Text] [Related]
55. The Hippo transducer TAZ promotes cell proliferation and tumor formation of glioblastoma cells through EGFR pathway.
Yang R; Wu Y; Zou J; Zhou J; Wang M; Hao X; Cui H
Oncotarget; 2016 Jun; 7(24):36255-36265. PubMed ID: 27167112
[TBL] [Abstract][Full Text] [Related]
56. Quantitative analysis of [11C]-erlotinib PET demonstrates specific binding for activating mutations of the EGFR kinase domain.
Petrulli JR; Sullivan JM; Zheng MQ; Bennett DC; Charest J; Huang Y; Morris ED; Contessa JN
Neoplasia; 2013 Dec; 15(12):1347-53. PubMed ID: 24403856
[TBL] [Abstract][Full Text] [Related]
57. Evaluation of radioiodinated quinazoline derivative as a new ligand for EGF receptor tyrosine kinase activity using SPECT.
Hirata M; Kanai Y; Naka S; Matsumuro K; Kagawa S; Yoshimoto M; Ohmomo Y
Ann Nucl Med; 2011 Feb; 25(2):117-24. PubMed ID: 21058048
[TBL] [Abstract][Full Text] [Related]
58. Inhibition of DHHC20-Mediated EGFR Palmitoylation Creates a Dependence on EGFR Signaling.
Runkle KB; Kharbanda A; Stypulkowski E; Cao XJ; Wang W; Garcia BA; Witze ES
Mol Cell; 2016 May; 62(3):385-396. PubMed ID: 27153536
[TBL] [Abstract][Full Text] [Related]
59. Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker.
Solca F; Dahl G; Zoephel A; Bader G; Sanderson M; Klein C; Kraemer O; Himmelsbach F; Haaksma E; Adolf GR
J Pharmacol Exp Ther; 2012 Nov; 343(2):342-50. PubMed ID: 22888144
[TBL] [Abstract][Full Text] [Related]
60. Identification of a novel fusion gene HMGA2-EGFR in glioblastoma.
Komuro A; Raja E; Iwata C; Soda M; Isogaya K; Yuki K; Ino Y; Morikawa M; Todo T; Aburatani H; Suzuki H; Ranjit M; Natsume A; Mukasa A; Saito N; Okada H; Mano H; Miyazono K; Koinuma D
Int J Cancer; 2018 Apr; 142(8):1627-1639. PubMed ID: 29193056
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
